Abstract: A method for treating and alleviating melanomas and various cancers characterized by the expression of VEGF-D by the tumor, the method comprising screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist to prevent binding of VEGF-D; methods for screening for neoplastic diseases, where detection of VEGF-D on or in cells such as tumor cells, blood vessel endothelial cells, lymph vessel endothelial cells, and/or cells with potential neoplastic growth indicates neoplastic disease; a method for promoting and maintaining vascularization of normal tissue in an organism by administering VEGF-D or a fragment or analog thereof; methods for screening tumors for metastatic risk where expression of VEFG-D by the tumor indicates metastatic risk; and methods to detect micro-metastasis of neoplastic disease where detection of VEGF-D on or in a tissue sample indicates metastasis of neoplastic disease.

Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Abstract: The present invention relates to immunointeractive molecules and their use in therapeutics and diagnostics. More particularly, the present invention provides antibodies that bind to NYK/flk-1 receptors, in particular the extracellular domain.

Abstract: The present invention relates to proteins having receptor-type tyrosine kinase-like properties which represent a novel family of proteins related to protein tyrosine kinases. The present invention relates to the full length proteins and to subunits, mutants, derivatives and/or analogues thereof and to nucleotide sequences encoding same. The present invention also extends to ligands for the above proteins and to pharmaceutical compositions comprising the proteins and/or mutants, derivatives and/or analogues thereof and/or ligands thereto.